dc.contributor.author | Kotloff, Karen L. | |
dc.contributor.author | Taylor, David N. | |
dc.contributor.author | Sztein, Marcelo B. | |
dc.contributor.author | Wasserman, Steven S. | |
dc.contributor.author | Losonsky, Genevieve | |
dc.contributor.author | Katz, David E. | |
dc.contributor.author | Campbell, James D. | |
dc.contributor.author | Levine, Myron M. | |
dc.contributor.author | Hale, Thomas L. | |
dc.date.accessioned | 2016-08-15T17:09:46Z | |
dc.date.available | 2016-08-15T17:09:46Z | |
dc.date.issued | 2002-04 | |
dc.identifier.citation | Kotloff, K. L., Taylor, D. N., Sztein, M. B., Wasserman, S. S., Losonsky, G. A., Nataro, J. P., … Hale, T. L. (2002). Phase I Evaluation of ΔvirG Shigella sonnei Live, Attenuated, Oral Vaccine Strain WRSS1 in Healthy Adults . Infection and Immunity, 70(4), 2016–2021. http://doi.org/10.1128/IAI.70.4.2016-2021.2002 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/21326 | |
dc.description.abstract | We conducted a phase I trial with healthy adults to evaluate WRSS1, a live, oral ΔvirG Shigella sonnei vaccine candidate. In a double-blind, randomized, dose-escalating fashion, inpatient volunteers received a single dose of either placebo (n = 7) or vaccine (n = 27) at 3 × 103 CFU (group 1), 3 × 104 CFU (group 2), 3 × 105 CFU (group 3), or 3 × 106 CFU (group 4). The vaccine was generally well tolerated, although a low-grade fever or mild diarrhea occurred in six (22%) of the vaccine recipients. WRSS1 was recovered from the stools of 50 to 100% of the vaccinees in each group. The geometric mean peak anti-lipopolysaccharide responses in groups 1 to 4, respectively, were 99, 39, 278, and 233 for immunoglobulin (IgA) antibody-secreting cell counts; 401, 201, 533, and 284 for serum reciprocal IgG titers; and 25, 3, 489, and 1,092 for fecal IgA reciprocal titers. Postvaccination increases in gamma interferon production in response to Shigella antigens occurred in some volunteers. We conclude that WRSS1 vaccine is remarkably immunogenic in doses ranging from 103 to 106 CFU but elicits clinical reactions that must be assessed in further volunteer trials. | en_US |
dc.publisher | American Society for Microbiology | en_US |
dc.rights | Copyright © 2002, American Society for Microbiology | en_US |
dc.title | Phase I Evaluation of ΔvirG Shigella sonnei Live, Attenuated, Oral Vaccine Strain WRSS1 in Healthy Adults | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Picking, William D. | |
kusw.kudepartment | Pharmaceutical Chemistry | en_US |
dc.identifier.doi | 10.1128/IAI.70.4.2016-2021.2002 | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | en_US |
kusw.oapolicy | This item does not meets KU Open Access policy criteria. | en_US |
dc.rights.accessrights | openAccess | |